TEC
ENSG00000135605
Target class
Kinase
Chromosome
4
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Other names
- PSCTK4
- Target name
- TEC
- Gene name
- Tec protein tyrosine kinase
- Gene symbol
- TEC
- Protein name
- Tyrosine-protein kinase Tec (EC 2.7.10.2)
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing|SH2 domain containing|Tec family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 33.76
- Tissue specificity (Gini)
- 0.574
- Tissue specificity (tau)
- 0.938
- KEGG gene identifiers
- hsa:7006
- Protein interaction confidence
- 0.895455
- Protein interaction partners
- 11
- R-HSA-1433557
- R-HSA-2871809
- R-HSA-512988
- End position
- 48269858
- Start position
- 48135783
- Chromosome
- 4
- Strand
- Reverse
- Cytoplasm. Cell membrane
- Peripheral membrane protein. Cytoplasm, cytoskeleton. Note=Following B-cell or T-cell receptors activation by antigen, translocates to the plasma membrane through its PH domain. Thrombin and integrin engagement induces translocation of TEC to the cytoskeleton during platelet activation. In cardiac myocytes, assumes a diffuse intracellular localization under basal conditions but is recruited to striated structures upon various stimuli, including ATP (By similarity). .
- Plasma membrane
- Tissue specificity (tau)
- 0.938338
- Expression inequality (Gini)
- 0.574357
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 33.76
- Esophagus - Mucosa
- 8.26
- Skin - Sun Exposed (Lower leg)
- 8.01
- Skin - Not Sun Exposed (Suprapubic)
- 7.85
- Lung
- 5.19
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes33.76
- Esophagus - Mucosa8.26
- Skin - Sun Exposed (Lower leg)8.01
- Skin - Not Sun Exposed (Suprapubic)7.85
- Lung5.19
- Vagina4.88
- Testis4.17
- Spleen3.85
- Thyroid3.56
- Small Intestine - Terminal Ileum3.42
- Minor Salivary Gland3.3
- Fallopian Tube3.19
- Artery - Aorta2.97
- Adrenal Gland2.95
- Adipose - Subcutaneous2.59
- Artery - Tibial2.54
- Nerve - Tibial2.53
- Bladder2.33
- Breast - Mammary Tissue2.32
- Cervix - Endocervix2.29
- Cervix - Ectocervix2.26
- Uterus2.2
- Colon - Transverse2.17
- Pituitary2.05
- Adipose - Visceral (Omentum)2.05
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007229
- GO:0010543
- GO:0035556
- GO:0050853
- GO:0005829
- GO:0005856
- GO:0005886
- GO:0004715
- GO:0005515
Related records
Trials (56)
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
- A Renal Impairment Study for PF-06651600
- A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
- A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)
- A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
- A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food
- A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
- A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Drugs (2)
- Ritlecitinib TEC family kinase inhibitor
- Ritlecitinib tosylate TEC family kinase inhibitor